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ABSTRACT 
 
 
BACKGROUND: Underlying mechanisms behind the hypothesized relationship between 
periodontal disease (PD) and coronary heart disease (CHD) have been insufficiently 
explored. We evaluated associations between self-reported tooth loss, a marker of PD, and 
prognostic biomarkers in 15,456 (97%) patients with stable CHD in the global STABILITY 
trial. 
METHODS AND RESULTS: Baseline blood samples were obtained and patients reported 
their number of teeth according to the following tooth loss levels: “26–32 (All)” [lowest 
level], “20–25”, “15–19”, “1–14”, and “No Teeth” [highest level]. Linear and Cox regression 
models assessed associations between tooth loss levels, biomarker levels and the relationship 
between tooth loss levels and outcomes, respectively. 
After multivariable adjustment, the relative biomarker increase between the 
highest and the lowest tooth loss level was: high-sensitivity C-reactive protein 1.21 (95% 
confidence interval, 1.14-1.29), interleukin 6 1.14 (1.10-1.18), lipoprotein-associated 
phospholipase A2 activity 1.05 (1.03-1.06), growth differentiation factor 15 1.11 (1.08-1.14), 
and N-terminal pro−B-type natriuretic peptide (NT-proBNP) 1.18 (1.11-1.25). No association 
was detected for high-sensitivity troponin T 1.02 (0.98-1.05). Some attenuation of the 
relationship between tooth loss and outcomes resulted from the addition of biomarkers to the 
multivariable analysis, of which NT-proBNP had the biggest impact. 
CONCLUSIONS: A graded and independent association between tooth loss and several 
prognostic biomarkers was observed, suggesting that tooth loss and its underlying 
mechanisms may be involved in multiple pathophysiological pathways also implicated in the 
development and prognosis of CHD. The association between tooth loss and cardiovascular 
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death and stroke persisted despite comprehensive adjustment including prognostic 
biomarkers. 
 
 
Clinical trial registration: www.clinicaltrials.gov; NCT00799903 
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1. INTRODUCTION 
 
There is a growing body of evidence favouring an independent association between oral 
health and coronary heart disease (CHD) [1–3]. We have recently reported an association 
between tooth loss and cardiovascular (CV) outcomes, but not myocardial infarction (MI), in 
a chronic CHD population [4]. In the literature, the hypothesized relationship between dental 
disease and CV disease is often attributed to deleterious effects of periodontal disease (PD), a 
highly prevalent chronic inflammatory condition ranging from early gingivitis to end-stage 
tooth loss, on the atherosclerotic process but the specific mechanistic nature of such a 
relationship remains elusive and debated [5]. 
Pathophysiological information on multiple aspects of etiology and progression 
of CV disease is reflected by several biomarkers, many of which also have robust capabilities 
of predicting prognosis [6–11]. Thus, associations between markers of PD, biomarkers and 
CV outcomes could provide further insights about possible mechanisms connecting PD and 
CV disease. However, such existing observations mainly stem from smaller populations and 
are limited to selected inflammatory markers such as C-reactive protein and interleukin-6 
[12,13], whereas reported associations with other important biomarkers are either scarce or 
non-existent. 
We evaluated associations between self-reported tooth loss, a marker of oral 
disease and PD, and a wide range of prognostic biomarkers, including high-sensitivity 
C-reactive protein (hs-CRP), interleukin-6 (IL-6), lipoprotein-associated phospholipase A2 
activity (Lp-PLA2), growth differentiation factor 15 (GDF-15), high-sensitivity troponin T 
(hs-Troponin T) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in a large global 
CHD population. Further, we assessed the influence of these biomarkers on the ability of 
self-reported tooth loss to predict CV outcomes. 
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2. METHODS 
 
2.1. Study population 
The STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY 
(STABILITY) study evaluated the efficacy of darapladib, an oral inhibitor of lipoprotein- 
associated phospholipase A2 activity (Lp-PLA2) compared to placebo in addition to optimal 
medical treatment in 15,828 participants from 39 countries with stable CHD, defined as prior 
myocardial infarction (MI), prior coronary revascularization (percutaneous coronary 
intervention or coronary artery bypass grafting), or multivessel CHD without 
revascularization. At least one additional enrichment criterion was required: age ≥60 years; 
diabetes mellitus requiring pharmacotherapy; high-density lipoprotein cholesterol 
 
<1.03mmol/L; current or previous smoker defined as ≥5 cigarettes per day on average; 
moderate renal dysfunction (estimated glomerular filtration rate ≥30 and <60mL/min/1.73 m2 
or urine albumin:creatinine ratio ≥30mg albumin/g creatinine); or polyvascular disease (co- 
existing disease in at least two arterial territories). Patients with an estimated glomerular 
filtration rate <30mL/min/1.73 m2 were excluded [14]. After a median follow-up of 3.7 years, 
no difference in major adverse cardiovascular events (MACE, i.e. first occurrence of CV 
death, myocardial infarction or stroke) was observed for patients randomized to darapladib 
compared to placebo [15]. The ethics committees of each participating country approved the 
study and all patients provided written informed consent prior to inclusion. The STABILITY 
trial was performed in accordance with the Declaration of Helsinki. 
 
 
2.2. Data collection 
 
At baseline, 15,456 (97%) patients reported their number of teeth according to the following 
categories: “26–32 (All teeth)”, “20–25”, “15–19”, “1–14”, and “No Teeth”. For the purposes 
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of this report, these categories are termed tooth loss levels with 26-32 teeth corresponding to 
the lowest level and no teeth, the highest level. 
Blood samples for routine laboratory tests and storage for later analyses were 
obtained in all 15,456 patients at baseline and prognostic biomarker analyses were performed 
in the majority of patients. Plasma aliquots were stored at -70°C until biochemical analysis. 
All routine biochemical and hs-CRP analyses were performed at a central laboratory with 
standardized methods (Quest Diagnostics Clinical Laboratories, Inc., Valencia, California, 
USA). Plasma concentrations of hs-CRP were analyzed using a particle-enhanced 
immunonephelometry assay, CardioPhase© hsCRP, Siemens Healthcare. Plasma 
concentrations of high-sensitivity IL-6 were analyzed using an ELISA technique, R&D 
Systems Inc., Minneapolis, MN, U.S.A. Lp-PLA2 activity was measured in an automated 
enzyme assay system (PLAC® Test for Lp-PLA2 Activity, diaDexus, San Francisco, CA, 
USA). The other biomarker assays were performed at the UCR Laboratory at Uppsala 
University, Uppsala, Sweden, GDF-15 was measured with the GDF-15 precommercial assay 
(Roche Diagnostics, Penzberg, Germany), composed of a monoclonal mouse antibody for 
capture and a monoclonal mouse antibody fragment, [F(ab´)2], for detection in a sandwich 
assay format. Detection was based on an electrochemiluminiscence immunoassay using a 
ruthenium (II) complex label. Levels of hs-Troponin T and NT-proBNP were also determined 
by electrochemiluminescence (Roche Diagnostics, Penzberg, Germany). The Cobas   
Analytics e601 was used for the Roche immunoassays. 
 
 
2.3. Statistical analysis 
 
Baseline variables are presented as mean, standard deviation and percentages. Baseline 
biomarker levels are presented as median and interquartile range. Baseline biomarker levels 
by tooth loss level were compared using the Kruskal-Wallis tests. 
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To determine associations between tooth loss levels and biomarker levels, each 
biomarker was modelled as a function of tooth loss level (five levels). All biomarkers were 
analyzed on a log-transformed scale using linear models. Geometric mean ratios are presented 
with 95% confidence intervals (CI) with the lowest tooth loss level (26-32 teeth) as  
reference, and according to three adjustment models. Model 1 adjusted for randomized 
treatment. Model 2 adjusted for Model 1 and prior MI, prior coronary revascularization, 
multi-vessel CHD, age, sex, geographic region, diabetes mellitus, hypertension, renal 
dysfunction, body mass index, smoking (current, former or never), systolic blood pressure 
and polyvascular disease. Model 3 adjusted for Model 2 and estimated glomerular filtration 
rate (according to The Chronic Kidney Disease Epidemiology Collaboration equation, 
replacing significant renal dysfunction) [16], hemoglobin, white blood cells, low-density 
lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides. Cox 
proportional hazards models were used to calculate hazard ratios for MACE, CV death and 
stroke in relation to tooth loss levels, adjusting for biomarkers in addition to a previously 
reported multivariable model [4], co-variables of which are also listed in Table 3. In these 
models, all biomarkers except Lp-PLA2 activity were added after log-transformation. The 
association between tooth loss and MI has previously been found to be absent in this cohort 
and was not re-analysed in the present analysis. 
 
A p-value <0.05 was considered statistically significant in all analyses. Analyses were 
performed at the Uppsala Clinical Research Center, Uppsala, Sweden using SAS version 9.3 
(SAS Institute, Inc., Cary, NC, USA). 
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3. RESULTS 
 
 
 
3.1. Baseline characteristics and associations with biomarkers 
Patients with higher tooth loss levels were older, were more likely to be female and had a 
greater CV risk factor burden, particularly a higher prevalence of smoking, diabetes mellitus, 
hypertension and impaired renal function compared to those with lower tooth loss levels 
(Table 1). Patients with more tooth loss had progressively higher baseline levels of hs-CRP, 
IL-6, Lp-PLA2 activity, GDF-15, hs-Troponin T and NT-proBNP (Table 2). As demonstrated 
in Figure 1, higher tooth loss levels were associated with progressively greater relative 
increases for all prognostic biomarkers in relation to the lowest tooth less level in Model 1. 
 
After multivariable adjustment the association remained statistically significant for all 
biomarkers, except for hs-Troponin T. 
 
 
3.2. Tooth loss and outcomes 
 
Table 3 demonstrates the association between a one-level increase in tooth loss and the risk 
of MACE, CV death and stroke according to the three adjustment models after a median 
follow-up of 3.7 years. The data up until Model 2 have been previously presented [4] 
showing a relative risk increase of 1.06, 1.17 and 1.14 for MACE, CV death and for stroke, 
respectively, for every one-level increase in tooth loss. The subsequent addition of 
biomarkers, individually and in groups, only attenuated the results slightly. Nevertheless, the 
addition of IL-6 and NT-proBNP rendered the association with MACE non-significant. 
Despite adjustment for all biomarkers and other co-variables, the association between tooth 
loss and CV death and stroke persisted. 
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4. DISCUSSION 
 
We found that tooth loss, a marker of PD, was associated with higher levels of several CV 
biomarkers indicating a potential relationship between tooth loss and several 
pathophysiological mechanisms relevant to CV morbidity and mortality, including 
inflammation, cellular integrity and myocardial dysfunction [6,7,9,17]. Adjustment for the 
biomarkers somewhat attenuated the risk of adverse outcome, signalling a potential relevance 
of the pathways they represent in the relationship between tooth loss and increased CV risk. 
However, much of the risk increase remained, suggesting that other and presently unknown 
mechanisms could be of importance, although confounding cannot be excluded. 
The host-mediated inflammatory response to PD constitutes the most 
commonly proposed mechanism linking oral disease with CHD and CV disease [18], mainly 
based on evidence from smaller studies of moderate associations between various measures 
of PD and elevation of inflammatory markers [12,13,19] and studies showing reductions of 
CRP and IL-6 levels after PD treatment [20]. This is the first study to corroborate these 
findings on a large scale in a global CHD population, including both upstream and 
downstream inflammatory markers, with comprehensive adjustment and with tooth loss as 
the exposure measure. Moreover, the association with Lp-PLA2 activity, previously only 
assessed in small patient populations [21], could represent an additional alternative and 
 
independent inflammatory link [22]. However, our findings could represent a challenge to the 
inflammation hypothesis as the highest levels of inflammatory markers were observed among 
the edentulous, who are most likely rid of oral substrates for inflammation. This could indicate 
that intrinsic factors and not PD explain the inflammatory activity, for       instance pro-
inflammatory genetic traits and epigenetic modifications common to both advanced PD and 
CHD [23,24]. However, it is also conceivable that many years’ exposure to chronic oral 
inflammation could instigate a secondary response in other locations, e.g. 
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atherosclerosis in blood vessels, which in turn could promote or maintain an elevated 
systemic inflammatory response. 
Associations with biomarkers that reflect other than inflammatory processes 
could suggest a relevance of alternative pathophysiological pathways in the tooth loss-CV 
disease relationship. The association with GDF-15 for instance, has not been previously 
described and could partly reflect a relationship between tooth loss and inflammation but also 
other harmful mechanisms [17] of relevance to several cardiac afflictions, including MI and 
heart failure, to which GDF-15 has been previously associated [25,26]. An independent 
association with cardiac biomarkers could support a more specific link between tooth loss, its 
antecedents, and cardiac pathology. This was previously investigated in a small study where 
44 patients with clinical evidence of PD had higher levels of troponin and NT-proBNP 
compared to controls, however these associations were unadjusted [27]. The association with 
NT-proBNP in our study suggests a relationship between tooth loss and baseline cardiac 
dysfunction that persisted after adjustment for traditional important heart failure determinants, 
including prior MI, hypertension and diabetes. Cross-reactivity between periodontal            
and myocardial antigens and chronic toll-like receptor activation have been                
suggested as potential mechanisms linking chronic infection, e.g. PD, to heart failure [28].  
Furthermore, a recent study demonstrated a greater burden of PD among patients with 
advanced HF awaiting heart transplantation compared to controls without HF. However, the 
observed differences were attenuated to non-significance after adjustment for markers of oral 
hygiene, race and 25-  hydroxyvitamin D levels [29]. Overall, data on the role of PD in the 
pathophysiology of heart failure is largely lacking but the results from our present study and 
other studies are interesting from a hypothesis generating perspective and should be explored 
further. 
Conversely to the association with NT-proBNP, tooth loss did not appear to be related to 
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mechanisms generating elevated levels of troponin [30], which is an interesting finding 
concurrent with the absent association between tooth loss and MI in this population [4]. 
In contrast to the absent MI association we recently reported a significant 
association between tooth loss and MACE, CV death and stroke. Although the demonstrated  
risk increases were relatively modest between adjacent tooth loss levels, they were more 
substantial and likely to be clinically relevant when comparing patients with severe or  
complete tooth loss to those with little or no tooth loss, particularly for CV death and stroke  
[4]. In the present analysis, we added biomarkers to the previous outcomes model to assess 
their influence on the demonstrated relationship between tooth loss and prognosis. Of the 
inflammatory markers, IL-6, an upstream marker, attenuated the results the most and 
eliminated the MACE association, supporting the hypothesis of inflammation as a mediator in 
the PD-CV outcomes relationship further. However, for most of the biomarkers, resulting 
attenuations were relatively small. The addition of NT-proBNP had the most pronounced 
attenuating effect on the risk of adverse outcome, indicating a prognostic relevance of the 
observed relationship between tooth loss and baseline myocardial dysfunction. The fact that a 
significant portion of the increased risk for CV death and stroke persisted despite full 
adjustment implies that alternate and presently unidentified pathways could be involved. The 
observation of stronger associations for CV death and stroke compared to MI further suggests 
that such pathways may be other than atherosclerotic and inflammatory, which is also 
consistent with the associations to biomarkers reflecting other than primarily inflammatory 
mechanisms, including GDF-15 and NT-proBNP. While the additional adjustment for 
biomarkers could lead to underestimation of the true influence of tooth loss on prognosis by 
removing effects of potential intermediate pathways, it also likely lessens the impact of 
residual confounding, which is undoubtedly a considerable obstacle when assessing causality. 
Nevertheless, as our findings are purely observational, causality cannot be inferred and they 
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may in fact be a product of long-term influence by causal factors common to both tooth loss 
and CV disease. 
From a prediction perspective and irrespective of causality, the observations 
show promise for the potential use of self-reported tooth loss as a prognostication tool in 
chronic CHD. Given its ability to predict several important outcomes combined with other 
qualities, including its straightforward obtainability and affordability, the clinical predictive 
utility of self-reported tooth loss should be explored further. 
 
 
4.1. Study limitations 
 
Self-reported tooth loss was the sole marker of PD in this analysis and the use of additional 
exposure measures, e.g. clinical, could have provided better information regarding the 
underlying etiology of tooth loss in the individual subjects. However, the literature generally 
exhibits a lack of consistency in the use of PD definitions [5] and PD has been shown to be 
the most common cause of tooth loss in older populations [31], although other causes, most 
importantly caries, must be acknowledged. Moreover, self-reported tooth loss has been 
validated against number of teeth on clinical examination with concurring results [32]. The 
cross-sectional multivariable analysis of the association between tooth loss and biomarker 
levels did not include markers of socioeconomic status, which could be important 
confounders. Finally, the analysis does not specifically disclose the nature of the observed 
associations, i.e. whether tooth loss and its underlying mechanisms increases CV risk or vice 
versa, or if the two conditions are driven by a common etiology. 
 
 
4.2. Conclusion 
 
Self-reported tooth loss was associated with progressively higher levels of several prognostic 
CV biomarkers suggesting possible involvement of tooth loss-generating mechanisms, 
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including PD, in multiple pathophysiological pathways relevant to both CHD development 
and prognosis. Adjustment for a wide range of CV risk factors, socioeconomic status and 
biomarkers eliminated the association with MACE but the association with CV death and 
stroke persisted. 
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FIGURE LEGENDS 
 
Figure 1 legend. Geometric mean ratio of biomarker levels according to tooth loss level with 
the lowest tooth loss level (26-32 teeth) as reference. Included biomarkers are high-sensitivity 
C-reactive protein (hs-CRP), interleukin 6 (IL-6), lipoprotein-associated phospholipase A2 
activity (Lp-PLA2), growth differentiation factor 15 (GDF-15), high-sensitivity troponin T 
(hs-Troponin T), and N-terminal pro−B-type natriuretic peptide (NT-proBNP). 
 
Adjusted for darapladib treatment, prior MI, prior revascularization, multi-vessel coronary 
heart disease, age, sex, geographic region, diabetes mellitus, hypertension, body mass index, 
smoking (current, former or never), systolic blood pressure, polyvascular disease, estimated 
glomerular filtration rate, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), 
hemoglobin, white blood cells, low-density lipoprotein (LDL) cholesterol, high-density 
lipoprotein (HDL) cholesterol, and triglycerides. 
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TABLES 
 
 
Table 1. Demographic and baseline characteristics by tooth loss level 
 
 
 
Tooth Loss Level 
 
Lowest Highest 
1394 
1395 
1396 
Characteristics All Patients 
 
(n=15456) 
26-32 Teeth 
 
(n=3310) 
20-25 Teeth 
 
(n=3680) 
15-19 Teeth 
 
(n=2167) 
1-14 Teeth 
 
(n=3785) 
No Teeth 
 
(n=2514) 
p-value 
1397    
1398 
1399 
1400 
Age, years 64.4 +/- 9.3 61.1 +/- 10.0 63.2 +/- 9.2 64.5 +/- 9.0 65.8 +/- 8.5 68.2 +/- 8.0 <0.0001 
 
Sex <0.0001 
 
1401 
1402 
1403 
1404 
1405 
1406 
1407 
1408 
1409 
1410 
1411 
1412 
1413 
1414 
1415 
Female 18.6 13.7 15.1 19.9 21.6 24.9  
Smoking status       <0.0001 
Never smoked 30.8 38.9 32.9 30.0 27.2 22.9  
Former smoker 51.2 46.2 50.5 50.4 53.2 56.6  
Current smoker 18.0 14.9 16.5 19.6 19.6 20.5  
Diabetes 38.8 35.4 37.4 36.6 41.3 43.0 <0.0001 
Chronic kidney disease 30.2 23.9 27.3 31.4 32.7 38.0 <0.0001 
Prior MI 58.9 55.3 58.1 59.9 62.4 58.7 <0.0001 
1416 
1417 
Prior revascularization 74.9 76.9 75.6 73.5 72.8 75.7 0.0078 
1418         
1419     24    
1420         
1421         
1422 
1423 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1442 
1424 
Education 
1425 
1426 None 
1427 
 
 
3.6 
 
 
3.5 
 
 
2.6 
 
 
3.1 
 
 
3.8 
 
 
5.2 
<0.0001 
1428 1-8 years 
1429 
19.2 14.7 15.5 16.8 23.1 27.1  
1430 9-12 years 30.7 26.1 29.0 32.5 32.8 34.4  
1431 
1432 Trade school 18.2 14.5 17.8 19.7 20.7 18.6 
 
1433 
1434 College/university 
28.3 41.2 35.0 27.9 19.7 14.7  
1435 
1436 
Alcohol consumption/week 
      <0.0001 
1437 
None
 
1438 
54.8 53.6 50.1 51.8 57.1 62.1  
1439 1-4 drinks 
1440 
18.9 19.1 20.3 20.2 18.5 16.4  
1441 5-14 drinks 15.8 16.3 18.0 16.4 14.9 12.9  
1443 ≥15 drinks 10.5 11.0 11.6 11.7 9.5 8.7 
 
1444 
1445 Leisure time physical activity 
      0.0002 
1446        
1447 Sedentary 32.8 33.3 30.0 30.4 35.1 35.0  
1448 
1449 
Mild exercise 44.6 44.4 45.1 45.5 43.0 45.4  
1450 Moderate exercise 22.6 22.3 25.0 24.1 21.8 19.6  
1451         
1452 LDL cholesterol, mmol/L 2.2 ± 0.9 2.1 ± 0.8 2.2 ± 0.8 2.2 ± 0.8 2.3 ± 0.9 2.2 ± 0.8 <0.0001 
1453         
1454 HDL cholesterol, mmol/L 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 <0.0001 
1455         
1456 eGFR, mL/min/1.73m
2
 75.8 ± 18.1 78.7 ± 17.8 77.2 ± 17.8 75.3 ± 18.1 74.5 ± 18.2 72.3 ± 18.0 <0.0001 
1457         
1458         
1459         
1460     25    
1461         
1462         
 
1463 
1464 
1465 
1466 
1467 
1468 
1469 
1470 
1471 
1472 
1473 
1474 
1475 
1476 
1477 
1478 
1479 
1480 
1481 
1482 
1483 
1484 
1485 
1486 
1487 
1488 
1489 
1490 
1491 
1492 
1493 
1494 
1495 
1496 
1497 
1498 
1499 
1500 
1501 
1502 
1503 
 
 
 
Systolic BP, mmHg 131.5 ± 16.6 128.8 ± 16.0 131.3 ± 16.1 131.6 ± 17.0 132.6 ± 16.4 133.4 ± 17.3 <0.0001 
Diastolic BP, mmHg 78.7 ± 10.4 78.4 ± 10.2 78.7 ± 10.3 78.8 ± 10.4 79.2 ± 10.3 78.2 ± 10.6 <0.0001 
BMI, kg/m2 28.9 ± 5.0 28.5 ± 5.0 29.1 ± 5.1 28.9 ± 5.0 29.0 ± 4.8 29.3 ± 5.2 <0.0001 
 
 
Data are percentages and mean ± SD 
 
MI, myocardial infarction; LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration 
rate; BP, blood pressure; BMI, body mass index 
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1505 
1506 
1507 
1508 
1509 
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Table 2. Baseline biomarker levels by tooth loss level 
 
 
 
 
 
Tooth Loss Level 
1511 
Lowest Highest 
1512 
1513 
1514 
1515 
1516 
1517 
Biomarker All Patients 
(n=15456) 
hs-CRP, mg/L 
26-32 Teeth 
(n=3310) 
20-25 Teeth 
(n=3680) 
15-19 Teeth 
(n=2167) 
1-14 Teeth 
(n=3785) 
No Teeth 
(n=2514) 
p-value 
1518 
1519 
1520 
1521 
1522 
1523 
1524 
1525 
1526 
1527 
1528 
1529 
1530 
n 
 
Median (Q1; Q3) 
 
 
 
IL-6, pg/mL 
 
n 
 
Median (Q1; Q3) 
14076 
 
1.3 (0.6; 3.1) 
 
 
 
 
 
14263 
 
2.1 (1.4; 3.2) 
2977 
 
1.1 (0.5; 2.6) 
 
 
 
 
 
2974 
 
1.8 (1.3; 2.8) 
3389 
 
1.3 (0.6; 2.8) 
 
 
 
 
 
3400 
 
2.0 (1.4; 2.9) 
1972 
 
1.4 (0.7; 3.0) 
 
 
 
 
 
2007 
 
2.1 (1.4; 3.3) 
3467 
 
1.5 (0.7; 3.3) 
 
 
 
 
 
3545 
 
2.2 (1.5; 3.4) 
2271 
 
1.7 (0.8; 4.0) < 0.0001 
 
 
 
 
 
2337 
 
2.4 (1.7; 3.8) < 0.0001 
1531 
1532 
Lp-PLA2, μmol/min/L 
1533 
1534 
1535 
1536 
1537 
1538 
1539 
1540 
1541 
1542 
1543 
1544 
n 
 
Median 
(Q1; Q3) 
 
 
 
GDF-15, 
pg/mL 
14155 
 
173 (143; 204) 
2960 
 
171 (140; 203) 
3366 
 
172 (143; 202) 
1984 
 
172 (143; 204) 
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3520 
 
173 (144; 206) 
2325 
 
176 (148; 
207)
 
< 0.0001 
1545 
1546 
1547 
1548 
1549 
1550 
 
 
 
 
 
 
 
1557 
1558 
1559 
1560 
1561 
1562 
1563 
1564 
1565 
1566 
 
 
 
n 
 
Median (Q1; Q3) 
 
 
 
 
 
 
 
Median (Q1; Q3) 
 
 
 
NT-proBNP, ng/L 
 
 
 
14237 
 
1254 (915; 1827) 
 
 
 
 
 
 
 
9.3 (6.2; 14.2) 
 
 
 
2974 
 
1120 (824; 1615) 
 
 
 
 
 
 
 
8.5 (5.7; 12.7) 
 
 
 
3385 
 
1181 (876; 1709) 
 
 
 
 
 
 
 
8.7 (6.0; 13.3) 
 
 
 
2011 
 
1225 (907; 1792) 
 
 
 
 
 
 
 
9.4 (6.2; 14.3) 
 
 
 
3528 
 
1314 (962; 1888) 
 
 
 
 
 
 
 
9.8 (6.4; 14.8) 
 
 
 
2339 
 
1486 (1069; 2172) 
 
 
 
 
 
 
 
10.4 (6.9; 16.2) 
 
 
 
 
 
< 0.0001 
 
 
 
 
 
 
 
< 0.0001 
1567    
1568 
1569 
1570 
1571 
1572 
1573 
1574 
1575 
1576 
1577 
1578 
1579 
1580 
1581 
1582 
1583 
1584 
1585 
n 14181 2960 3392 2003 3505 2321  
Median (Q1; Q3) 173 (83; 377) 132 (64; 278) 152 (72; 328) 177 (88; 392) 202 (97; 450) 224 (108; 493) < 0.0001 
 
1551   
1552  
1553 hs-Troponin T, ng/L 
1554  
1555 n 14147 2952 3386 1996 3497 2316 
1556        
 
hs-
CRP, 
high-
sensi
tivity 
C-
reacti
ve 
prote
in; 
IL-6, 
interl
eukin 
6; 
Lp-
PLA2
, 
lipop
rotei
n-
assoc
iated 
phos
pholi
pase 
A2 
activi
ty; 
hs-
Trop
onin 
T, 
high-
sensi
tivity 
tropo
nin 
 
T; 
NT-
proB
NP, 
N-
termi
nal 
pro−
B-
type 
natri
uretic peptide; GDF-15, growth differentiation factor 15 
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1586 
1587 
1588 
1589 
1590 
1591 
1592 
 
 
Table 3. Risk of major adverse cardiac events (MACE), cardiovascular (CV) death and stroke for one increase in tooth loss level after 
adjustment for risk factors and biomarkers 
1593    
1594 
1595 
1596 
1597 
1598 
Adjustment MACE 
 
(HR [95% CI]) 
p-value CV death 
 
(HR [95% CI]) 
p-value Stroke 
 
(HR [95% CI]) 
p-value 
1599 
1600 
1601 
1602 
1603 
1604 
1605 
1606 
1607 
1608 
1609 
1610 
1611 
1612 
1613 
1614 
1615 
1616 
1617 
1618 
1619 
1620 
1621 
1622 
1623 
1624 
1625 
1626 
Model 1 
 
 
 
Model 2 
 
 
 
Model 2 + hs-
CRP 
 
 
 
Model 2 + IL-6 
1.16 
(1.12-
1.20) 
 
 
 
1.06 
(1.02-
1.10) 
 
 
 
1.05 
(1.00-
1.09) 
 
 
 
1.04 
(1.00-
1.09) 
<0.0001 
 
 
 
0.0041 
 
 
 
0.0404 
 
 
 
0.0581 
1.30 (1.23-1.37) 
<0.0001 
 
 
 
1.17 (1.10-1.24) 
<0.0001 
 
 
 
1.16 (1.08-1.23) 
<0.0001 
 
 
 
1.14 (1.07-1.22) 
<0.0001 
1.22 (1.23-1.32) 
 
 
 
1.14 (1.04-1.25) 
 
 
 
1.14 (1.04-1.23) 
 
 
 
1.12 (1.02-1.23) 
Model 2 + Lp-PLA2 1.06 (1.01-1.10) 0.0091 1.16 (1.09-1.24) <0.0001 1.14 (1.04-1.26) 0.0057 
 
Model 2 + GDF-15 
 
1.05 (1.01-1.10) 
 
0.0273 
 
1.15 (1.08-1.23) <0.0001 
 
1.12 (1.02-1.23) 
 
0.0188 
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<0
.
0
0
0
1 
 
 
 
0
.
0
0
6
2 
 
 
 
0
.
0
0
6
5 
 
 
 
0
.
0
2
2
4 
1627 
1628 
1629 
1630 
1631 
1632 
1633 
1634 
1635 
1636 
1637 
1638 
1639 
1640 
1641 
1642 
 
 
 
Model 2 + hs-Troponin T, NT-proBNP 
 
 
 
1.03 (0.99-1.07) 
 
 
 
0.1893 
 
 
 
1.12 (1.05-1.19) 
 
 
 
0.0006 
 
 
 
1.10 (1.00-1.21) 
 
 
 
0.0488 
1643 
1644 
1645 
1646 
1647 
HR, hazard ratio; CI, confidence interval; Model 1 is adjusted for study treatment only. Model 2 is adjusted for model 1 and age, systolic blood pressure, diastolic blood 
pressure, BMI, LDL cholesterol, HDL cholesterol, history of diabetes, prior MI, sex, smoking status, waist hip ratio, eGFR, family history of coronary heart disease, alcohol 
consumption, years of education, level of physical activity and country income level. Abbreviations as in Tables 1 and 2. 
Model 2 + hs-CRP, IL-6, Lp-PLA2, 1.04 (0.99-1.08) 0.0973 1.13 (1.05-1.20) 0.0005 1.13 (1.03-1.25) 0.0146 
GDF-15       
 
Model 2 + hs-CRP, IL-6, Lp-PLA2, 
 
GDF-15, hs-Troponin T, NT-proBNP 
 
1.02 (0.98-1.07) 
 
0.3335 
 
1.10 (1.03-1.18) 
 
0.0046 
 
1.11 (1.00-1.23) 
 
0.0406 
 
1648  
1649 
1650 
1651 
1652 
1653 
1654 
1655 
1656 
1657 
1658 
1659 
1660 
1661 
1662 
1663 
1664 
1665 30 
1666  
1667  
 
 1668  
1669 
1670 
1671 
1672 
1673 
1674 
1675 
1676 
1677 
1678 
1679 
1680 
1681 
1682 
1683 
1684 
1685 
1686 
1687 
1688 
1689 
1690 
1691 
1692 
1693 
1694 
1695 
1696 
1697 
1698 
1699 
1700 
1701 
1702 
1703 
1704 
1705 
1706 
1707 
1708 
1709 
1710 
1711 
1712 
1713 
1714 
1715 
1716 
1717 
1718 
1719 
1720 
1721 
1722 
1723 
1724 
1725 31 
1726  
Biomarker 
and tooth Mean (95% 
loss level ratio Cl) P-value 
 
 
0.9 0.95 1 1.05 1.1 1.15 1.2 1.25 1.3 
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